- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07558980
Platelet-Rich Plasma Composition and Clinical Effects in Knee Osteoarthritis
Study of the Composition of Platelet-rich Plasma and Its Clinical and Molecular Effect in the Biological Treatment of Knee Arthrosis
연구 개요
상세 설명
The study is designed as an observational, longitudinal, prospective cohort investigation focused on patients with primary degenerative pathology of the knee joint, specifically primary gonarthrosis. The target population includes individuals diagnosed with knee osteoarthritis, while the accessible population consists of patients admitted to the Clinical Rehabilitation Hospital in Cluj-Napoca.
A total of 40 consecutive patients meeting inclusion criteria will be enrolled. Each participant will undergo treatment consisting of an intra-articular injection of platelet-rich plasma (PRP) at the knee level. The consecutive inclusion approach reduces selection bias and reflects routine clinical practice.
A central component of the study is the biological characterization of PRP. The investigators will analyze its composition, particularly focusing on growth factors such as platelet-derived growth factor (PDGF), transforming growth factor beta 1 (TGF-β1), and insulin-like growth factor 1 (IGF-1). This analysis is intended to contribute to the standardization of PRP therapy in knee osteoarthritis.
In parallel, the study will assess systemic inflammatory status by measuring circulating biomarkers, including interleukins (IL-1β, IL-8, IL-18) and tumor necrosis factor alpha (TNF-α). Monitoring these biomarkers allows evaluation of the inflammatory response and provides insight into the biological effects of PRP on the intra-articular environment.
Overall, the study seeks to clarify both the pathophysiological mechanisms underlying knee osteoarthritis and the therapeutic mechanisms of PRP, while also assessing its clinical effectiveness through changes in inflammatory markers.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Cluj
-
Cluj-Napoca, Cluj, 루마니아, 400347
- " Iuliu Hatieganu" University of medicine and Pharmacy
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age between 40 and 80 years
- Diagnosis of unilateral or bilateral gonarthrosis radiological grade 2-3 Kellgren-Lawrence
- Knee joint pain greater than 4 on the VAS scale
- History of knee joint pain for at least 6 months
- Patients who are to receive an inpatient PRP injection
Exclusion Criteria:
- Diagnosis of secondary gonarthrosis
- History of inflammatory rheumatological disease or gout
- History of recent minor (1 month) or major (2 years) trauma to the knee joint
- History of knee surgery or arthroscopy
- Infiltrations, physiotherapy or other knee treatments in the last 3 months
- Diagnosis of neoplasia, hematological or immunological diseases
- Clinical or biological signs of acute infection
- Coagulation disorders
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: 40 patients with knee arthrosis receiving an infiltration with plasma rich in platelets
intra-articular administration of plasma rich in platelets (PRP)
|
intraarticular injection
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain intensity
기간: Baseline and at 4 weeks
|
Pain intensity assessed using the Visual Analogue Scale (VAS)
|
Baseline and at 4 weeks
|
|
Functional status and symptom severity
기간: Basline and at 4 weeks
|
Functional status and symptom severity measured by the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire Health-related quality of life evaluated with the SF-36 questionnaire
|
Basline and at 4 weeks
|
|
Systemic inflammatory markers
기간: Baseline and at 4 weeks
|
Systemic inflammatory markers: IL-1β, IL-8, IL-18, TNF-α
|
Baseline and at 4 weeks
|
|
General inflammatory indicators
기간: Baseline and at 4 weeks
|
General inflammatory indicators: erythrocyte sedimentation rate (ESR)
|
Baseline and at 4 weeks
|
|
General inflammatory indicators 2
기간: Baseline and at 4 weeks
|
General inflammatory indicators: C-reactive protein (CRP)
|
Baseline and at 4 weeks
|
|
Growth factor profile of PRP
기간: Baseline
|
transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF)
|
Baseline
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IuliuHatieganuUniversity
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .